Why Novavax Stock Could Skyrocket in December

Don't forget about Novavax (NASDAQ: NVAX). It could be easy for investors to do so. The company's COVID-19 vaccine still isn't authorized in any major market. Its shares are more than 30% below the high set early this year and remain 20% lower than where they traded just three months ago.

But I think the chances are very good that Novavax is poised to soon take off. Here's why Novavax stock could skyrocket in December.

Image source: Getty Images.

Continue reading

Source Fool.com